ReAlta’s efforts are focused on developing therapies that leverage our unique dual targeting mechanisms in three therapeutic areas: Neurology, Pulmonary, and Hematology.
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.
Learn MoreAcute Exacerbations of COPD (AE COPD) affect individuals suffering from COPD, leading to worsening lung function and hospitalization. This inflammatory disease is primarily driven by neutrophils recruited into the lungs.
Learn MoreGraft-versus-Host Disease (GvHD) is a common disease following bone marrow transplantation where the transplanted white blood cells begin to attack the host body including skin, liver and intestines.
Learn MorePlatelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.
Learn More